A Randomized, Double-Blind, Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction
The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana addiction and withdrawal.
NCT00217971 — Marijuana Abuse
Status: Completed
http://inclinicaltrials.com/marijuana-abuse/NCT00217971/
North American Opiate Medication Initiative (NAOMI): Multi-Centre, Randomized Controlled Trial of Heroin-Assisted Therapy for Treatment-Refractory Injection Opiate Users
The objective of this study is to determine whether the closely supervised provision of injectable, pharmaceutical-grade heroin (in combination with oral methadone) is more effective than methadone therapy alone in recruiting, retaining, and benefiting long-term heroin users who have not been helped by current standard treatment options.
NCT00175357 — Opiate Addiction
Status: Completed
http://inclinicaltrials.com/opiate-addiction/NCT00175357/
Employment-Based Addiction Pharmacotherapy
A randomized study is planned over 5 years to evaluate the effectiveness of the Therapeutic Workplace in promoting naltrexone ingestion and abstinence in unemployed opiate-dependent injection drug users. Participants will be offered an opioid detoxification and naltrexone induction. Participants who complete the naltrexone induction will be randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and prescribed naltrexone for 26 weeks. The groups will differ in the contingencies imposed to work and earn salary. Work Plus Naltrexone Contingency participants will be required to ingest naltrexone to work, and will receive a brief pay decrease for missing a dose. Work Plus Naltrexone Prescription participants will be prescribed naltrexone, but will not be required to ingest it to work. This study will provide a rigorous evaluation of a novel employment-based intervention, the Therapeutic Workplace, to promote naltrexone ingestion and drug abstinence in a population of injection drug users who are at considerable risk of spreading or contracting HIV infection. Hypotheses being tested in this study are: Naltrexone ingestion will be maintained in the group exposed to the employment-based naltrexone treatment significantly more than the group exposed to usual-care treatment package. Opiate abstinence will be maintained in the group exposed to the employment-based naltrexone treatment significantly more than the group exposed to usual-care treatment package.
NCT00149669 — Opioid-Related Disorders
Status: Completed
http://inclinicaltrials.com/opioid-related-disorders/NCT00149669/
Heroin Addiction Treatment: Naltrexone and Adrenergic Agents
Naltrexone is a medication that is currently used to treat drug and alcohol addiction. Guanfacine is a medication that is currently used to manage the withdrawal symptoms in individuals undergoing opioid detoxification. A combination of these two medications may be beneficial in reducing heroin use in individuals addicted to heroin. This study will evaluate the effectiveness of naltrexone and guanfacine, alone and in combination, at reducing heroin use in heroin addicts.
NCT00142948 — Heroin Dependence
Status: Completed
http://inclinicaltrials.com/heroin-dependence/NCT00142948/
Lofexidine: Enhancing Naltrexone Treatment for Opiate Addiction
Lofexidine is an experimental medication that may be beneficial in reducing opiate withdrawal symptoms, such as sleep difficulty, anxiety, and tension. The purpose of this study is to determine whether lofexidine in combination with naltrexone can improve an individual's ability to cope with stress and subsequently increase the chances of remaining abstinent from opiates.
NCT00142909 — Opioid-Related Disorders
Status: Completed
http://inclinicaltrials.com/opioid-related-disorders/NCT00142909/
N-acetylcysteine as Treatment in Cocaine Addiction
Recent findings have suggested that N-acetylcysteine (NAC) substantially reduces cocaine drug-seeking behavior in formerly cocaine dependent rats. The purpose of this study is to determine the safety, tolerability, and cue reactivity effects of NAC in cocaine dependent individuals and non-dependent healthy controls.
NCT00136825 — Cocaine-Related Disorders
Status: Completed
http://inclinicaltrials.com/cocaine-related-disorders/NCT00136825/
Developing Medication For Tobacco Addiction: NMDA Agents
One of nicotine's effects on the body is at the level of the NMDA receptors in the brain. Memantine is a drug that also affects NMDA receptors, making it a candidate for the treatment of nicotine addiction. The purpose of this study is to evaluate the effectiveness of memantine using a laboratory model of tobacco addiction. The investigators will compare the effects of memantine with bupropion, medication currently used to facilitate smoking cessation.
NCT00136747 — Tobacco Use Disorder
Status: Completed
http://inclinicaltrials.com/tobacco-use-disorder/NCT00136747/
Marijuana Addiction and Depression: Venlafaxine Treatment
The purpose of this study is to determine if Venlafaxine Extended Release (Ven-XR) is effective in treating individuals with marijuana addiction and depression.
NCT00131456 — Depression
Status: Completed
http://inclinicaltrials.com/depression/NCT00131456/
Effects of Dynorphin 1-13 on Heroin Addiction
The purpose of this study is to evaluate the effects of IV dynorphin in humans during acute heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal, reduces opiate craving, and is safe at doses required to produce the above effects.
NCT00000244 — Opioid-Related Disorders
Status: Completed
http://inclinicaltrials.com/opioid-related-disorders/NCT00000244/
Buprenorphine Pharmacology Related to Addiction Treatment
The purpose of this study is to examine if chronic buprenorphine administration will generate supersensitivity to opiates.
NCT00000239 — Opioid-Related Disorders
Status: Completed
http://inclinicaltrials.com/opioid-related-disorders/NCT00000239/